A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

This study is ongoing, but not recruiting participants.

First Received: January 10, 2007 Last Updated: February 19, 2009 History of Changes

Sponsored by:	Adherex Technologies, Inc.
Information provided by:	Adherex Technologies, Inc.
ClinicalTrials.gov Identifier:	NCT00421811

Purpose

N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 with Normothermic Isolated Limb Infusion of Melphalan in subjects with locally advanced malignant melanoma.

Condition	Intervention	Phase
Neoplasms	Drug: ADH-1 Drug: melphalan	Phase I Phase II

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment
Official Title:	An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-Tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma (Adherex Protocol Number AHX-01-007).

Resource links provided by NLM:

MedlinePlus related topics: Cancer Melanoma

Drug Information available for: Melphalan Sarcolysin Melphalan hydrochloride

U.S. FDA Resources

Further study details as provided by Adherex Technologies, Inc.:

Primary Outcome Measures:

To tabulate the Best Overall Response according to unconfirmed RECIST, modified for cutaneous lesions [ Time Frame: By Week 12 ] [ Designated as safety issue: No ]

Estimated Enrollment:	56
Study Start Date:	April 2007
Estimated Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

Intervention Details:

4 gm IV Days 1 and 8

By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Signed written informed consent
Male and female patients > or = 18 years of age with diagnosis of melanoma for which treatment with Normothermic Isolated Limb Infusion (ILI) of melphalan would be appropriate
Measurable disease
Disease site(s) must be distal to the planned site of tourniquet placement
Available for immunohistochemical testing of N-cadherin expression tumor tissue
Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and ECG

Exclusion Criteria:

Receipt of ADH-1 prior to this clinical study (prior melphalan via ILI, is okay)
Stage IV melanoma
Chemotherapy, radiotherapy, or any other investigational drug within 4 weeks before study entry
History of tumors that have shown clinically significant evidence of active bleeding within 12 weeks before study entry
Stroke, major surgery, or other major tissue injury within 4 weeks before study entry
Uncontrolled congestive heart failure, coronary artery disease, or life threatening arrhythmias; myocardial infarction within 12 months; significant electrocardiogram (ECG) abnormalities
Allergic reaction to any therapeutic peptide or to melphalan

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00421811

Locations

United States, Colorado
University of Colorado, Denver
Aurora, Colorado, United States, 80045
United States, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612
University of Florida College of Medicine
Gainesville, Florida, United States, 32610
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27516
United States, Pennsylvania
Lehigh Valley Hospital
Allentown, Pennsylvania, United States, 18103
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Intermountain Medical Center
Murray, Utah, United States, 84157

Sponsors and Collaborators

Adherex Technologies, Inc.

Investigators

Principal Investigator:

Doug Tyler, MD

Duke University

More Information

Additional Information:

(Adherex Technologies Inc. Corporate Homepage) This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Adherex Technologies, Inc. ( Clinical Study Manager )
Study ID Numbers:	AHX-01-007
Study First Received:	January 10, 2007
Last Updated:	February 19, 2009
ClinicalTrials.gov Identifier:	NCT00421811 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Adherex Technologies, Inc.:

cancer
tumors
melanoma
anticarcinogenic agents

antineoplastic agents
cadherins
solid tumors

Study placed in the following topic categories:

Anticarcinogenic Agents
Melphalan
Immunologic Factors
Antineoplastic Agents, Alkylating

Alkylating Agents
Immunosuppressive Agents
Melanoma

Additional relevant MeSH terms:

Anticarcinogenic Agents
Melphalan
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Physiological Effects of Drugs
Protective Agents

Immunosuppressive Agents
Pharmacologic Actions
Neoplasms
Therapeutic Uses
Myeloablative Agonists
Antineoplastic Agents, Alkylating
Alkylating Agents

ClinicalTrials.gov processed this record on September 09, 2009